CLASRP oncogene as a novel target for colorectal cancer.


Journal

Functional & integrative genomics
ISSN: 1438-7948
Titre abrégé: Funct Integr Genomics
Pays: Germany
ID NLM: 100939343

Informations de publication

Date de publication:
02 Sep 2023
Historique:
received: 31 05 2023
accepted: 11 08 2023
revised: 04 08 2023
medline: 5 9 2023
pubmed: 4 9 2023
entrez: 2 9 2023
Statut: epublish

Résumé

Clk4-associated serine/arginine-rich protein (CLASRP), an alternative splicing regulator, may be involved in the development and progression of cancer by regulating the activity of the CDC-like kinase (Clk) family. This study explored the biological function of CLASRP in colorectal cancer (CRC). The expression of CLASRP, which is associated with clinicopathological features, was analysed in CRC tissues and paired noncancer tissues by RT-PCR. The roles of CLASRP were investigated in CRC cells transfected with plasmids or shRNA through proliferation, migration and invasion assays in vitro and a xenograft model in vivo. Apoptosis was analysed using CLASRP-overexpressing CRC cells by western blotting. Clk inhibitors were used to perform functional research on CLASRP in CLASRP-overexpressing CRC cells. CLASRP was significantly upregulated in CRC cell lines, while high CLASRP expression was correlated with metastasis in CRC patients. Functionally, overexpression of CLASRP significantly promoted the proliferation, migration and invasion of CRC cells in vitro and tumour growth in vivo. Mechanistically, the proliferation, migration and invasion of CLASRP-overexpressing CRC cells were inhibited by Clk inhibitors, accompanied by low expression of CLASRP at the gene and protein levels. Clk inhibitors induced apoptosis of CLASRP-overexpressing CRC cells, resulting in direct blockade of cell growth. The expression levels of cleaved caspase 3 and cleaved caspase 8 were increased in CLASRP-overexpressing CRC cells treated with Clk inhibitors. CLASRP might serve as a promotional oncogene in CRC cells and be suppressed by Clk inhibitors through activation of caspase pathways.

Identifiants

pubmed: 37658940
doi: 10.1007/s10142-023-01208-8
pii: 10.1007/s10142-023-01208-8
pmc: PMC10474993
doi:

Substances chimiques

CLASRP protein, human 0
Serine-Arginine Splicing Factors 170974-22-8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

290

Informations de copyright

© 2023. The Author(s).

Références

Babu N, Pinto SM, Biswas M, Subbannayya T, Rajappa M, Mohan SV, Advani J, Rajagopalan P, Sathe G, Syed N, Radhakrishna VD, Muthusamy O, Navani S, Kumar RV, Gopisetty G, Rajkumar T, Radhakrishnan P, Thiyagarajan S, Pandey A et al (2020) Phosphoproteomic analysis identifies CLK1 as a novel therapeutic target in gastric cancer. Gastric Cancer 23:796–810. https://doi.org/10.1007/s10120-020-01062-8
doi: 10.1007/s10120-020-01062-8 pubmed: 32333232
Bowler E, Porazinski S, Uzor S, Thibault P, Durand M, Lapointe E, Rouschop KMA, Hancock J, Wilson I, Ladomery M (2018) Hypoxia leads to significant changes in alternative splicing and elevated expression of CLK splice factor kinases in PC3 prostate cancer cells. BMC Cancer 18:355. https://doi.org/10.1186/s12885-018-4227-7
doi: 10.1186/s12885-018-4227-7 pubmed: 29606096 pmcid: 5879922
Bu T, Wang C, Jin H, Meng Q, Huo X, Sun H, Sun P, Wu J, Ma X, Liu Z, Liu K (2020) Organic anion transporters and PI3K-AKT-mTOR pathway mediate the synergistic anticancer effect of pemetrexed and rhein. J Cell Physiol 235:3309–3319. https://doi.org/10.1002/jcp.29218
doi: 10.1002/jcp.29218 pubmed: 31587272
Budihardjo I, Oliver H, Lutter M, Luo X, Wang X (1999) Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 15:269–290. https://doi.org/10.1146/annurev.cellbio.15.1.269
doi: 10.1146/annurev.cellbio.15.1.269 pubmed: 10611963
Colwill K, Pawson T, Andrews B, Prasad J, Manley JL, Bell JC, Duncan PI (1996) The Clk/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution. EMBO J 15:265–275
doi: 10.1002/j.1460-2075.1996.tb00357.x pubmed: 8617202 pmcid: 449941
El Marabti E, Younis I (2018) The cancer spliceome: reprograming of alternative splicing in cancer. Front Mol Biosci 5:80. https://doi.org/10.3389/fmolb.2018.00080
doi: 10.3389/fmolb.2018.00080 pubmed: 30246013 pmcid: 6137424
ElHady AK, Abdel-Halim M, Abadi AH, Engel M (2017) Development of selective Clk1 and -4 inhibitors for cellular depletion of cancer-relevant proteins. J Med Chem 60:5377–5391. https://doi.org/10.1021/acs.jmedchem.6b01915
doi: 10.1021/acs.jmedchem.6b01915 pubmed: 28561591
Fedorov O, Huber K, Eisenreich A, Filippakopoulos P, King O, Bullock AN, Szklarczyk D, Jensen LJ, Fabbro D, Trappe J, Rauch U, Bracher F, Knapp S (2011) Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing. Chem Biol 18:67–76. https://doi.org/10.1016/j.chembiol.2010.11.009
doi: 10.1016/j.chembiol.2010.11.009 pubmed: 21276940 pmcid: 3145970
Gao B, Wang Y, Lu S (2022) Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment. Funct Integr Genomics 23(1):6. https://doi.org/10.1007/s10142-022-00933-w
doi: 10.1007/s10142-022-00933-w pubmed: 36536232 pmcid: 9763151
Jeong S (2017) SR proteins: binders, regulators, and connectors of RNA. Mol Cells 40:1–9. https://doi.org/10.14348/molcells.2017.2319
doi: 10.14348/molcells.2017.2319 pubmed: 28152302 pmcid: 5303883
Katsu R, Onogi H, Wada K, Kawaguchi Y, Hagiwara M (2002) Novel SR-rich-related protein clasp specifically interacts with inactivated Clk4 and induces the exon EB inclusion of Clk. J Biol Chem 277:44220–44228. https://doi.org/10.1074/jbc.M206504200
doi: 10.1074/jbc.M206504200 pubmed: 12169693
Kim SM, Vetrivel P, Ha SE, Kim HH, Kim JA, Kim GS (2020) Apigetrin induces extrinsic apoptosis, autophagy and G2/M phase cell cycle arrest through PI3K/AKT/mTOR pathway in AGS human gastric cancer cell. J Nutr Biochem 83:108427. https://doi.org/10.1016/j.jnutbio.2020.108427
doi: 10.1016/j.jnutbio.2020.108427 pubmed: 32559585
Li FY, Lai MD (2009) Colorectal cancer, one entity or three. J Zhejiang Univ Sci B 10:219–229. https://doi.org/10.1631/jzus.B0820273
doi: 10.1631/jzus.B0820273 pubmed: 19283877 pmcid: 2650032
Liang Y, Song J, He D, Xia Y, Wu Y, Yin X, Liu J (2019) Systematic analysis of survival-associated alternative splicing signatures uncovers prognostic predictors for head and neck cancer. J Cell Physiol 234:15836–15846. https://doi.org/10.1002/jcp.28241
doi: 10.1002/jcp.28241 pubmed: 30740675 pmcid: 6618130
Lim S, Kaldis P (2013) Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development 140:3079–3093. https://doi.org/10.1242/dev.091744
doi: 10.1242/dev.091744 pubmed: 23861057
Madide T, Somboro AM, Amoako DG, Khumalo HM, Khan RB (2021) Di-2-picolylamine triggers caspase-independent apoptosis by inducing oxidative stress in human liver hepatocellular carcinoma cells. Biotechnol Appl Biochem 68:257–266. https://doi.org/10.1002/bab.1918
doi: 10.1002/bab.1918 pubmed: 32250477
Malumbres M (2014) Cyclin-dependent kinases. Genome Biol 15:122. https://doi.org/10.1186/gb4184
doi: 10.1186/gb4184 pubmed: 25180339 pmcid: 4097832
Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9:153–166. https://doi.org/10.1038/nrc2602
doi: 10.1038/nrc2602 pubmed: 19238148
Martin Moyano P, Nemec V, Paruch K (2020) Cdc-like kinases (CLKs): biology, chemical probes, and therapeutic potential. Int J Mol Sci 21:7549. https://doi.org/10.3390/ijms21207549
doi: 10.3390/ijms21207549 pubmed: 33066143 pmcid: 7593917
Muraki M, Ohkawara B, Hosoya T, Onogi H, Koizumi J, Koizumi T, Sumi K, Yomoda J, Murray MV, Kimura H, Furuichi K, Shibuya H, Krainer AR, Suzuki M, Hagiwara M (2004) Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem 279:24246–24254. https://doi.org/10.1074/jbc.M314298200
doi: 10.1074/jbc.M314298200 pubmed: 15010457
Ninomiya K, Adachi S, Natsume T, Iwakiri J, Terai G, Asai K, Hirose T (2020) LncRNA-dependent nuclear stress bodies promote intron retention through SR protein phosphorylation. EMBO J 39:e102729. https://doi.org/10.15252/embj.2019102729
doi: 10.15252/embj.2019102729 pubmed: 31782550
Salvesen GS, Riedl SJ (2008) Caspase mechanisms. Adv Exp Med Biol 615:13–23. https://doi.org/10.1007/978-1-4020-6554-5_2
doi: 10.1007/978-1-4020-6554-5_2 pubmed: 18437889
Shkreta L, Bell B, Revil T, Venables JP, Prinos P, Elela SA, Chabot B (2013) Cancer-associated perturbations in alternative pre-messenger RNA splicing. Cancer Treat Res 158:41–94. https://doi.org/10.1007/978-3-642-31659-3_3
doi: 10.1007/978-3-642-31659-3_3 pubmed: 24222354
Siegel RL, Miller KD, Wagle NS, Jemal A (2023a) Cancer statistics, 2023. CA Cancer J Clin 73:17–48. https://doi.org/10.3322/caac.21763
doi: 10.3322/caac.21763 pubmed: 36633525
Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A (2023b) Colorectal cancer statistics, 2023. CA Cancer J Clin 73:233–254. https://doi.org/10.3322/caac.21772
doi: 10.3322/caac.21772 pubmed: 36856579
Thornberry NA, Lazebnik Y (1998) Caspases: enemies within. Science 281:1312–1316. https://doi.org/10.1126/science.281.5381.1312
doi: 10.1126/science.281.5381.1312 pubmed: 9721091
Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, Garcia-Calvo M, Houtzager VM, Nordstrom PA, Roy S, Vaillancourt JP, Chapman KT, Nicholson DW (1997) A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J Biol Chem 272:17907–17911. https://doi.org/10.1074/jbc.272.29.17907
doi: 10.1074/jbc.272.29.17907 pubmed: 9218414
Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, Group EGW (2014) Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii1–iii9. https://doi.org/10.1093/annonc/mdu260
doi: 10.1093/annonc/mdu260 pubmed: 25190710
Wei C, Yang C, Wang S, Shi D, Zhang C, Lin X, Liu Q, Dou R, Xiong B (2019) Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol Cancer 18:64. https://doi.org/10.1186/s12943-019-0976-4
doi: 10.1186/s12943-019-0976-4 pubmed: 30927925 pmcid: 6441214
Wolf BB, Green DR (1999) Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem 274:20049–20052. https://doi.org/10.1074/jbc.274.29.20049
doi: 10.1074/jbc.274.29.20049 pubmed: 10400609
Xie F, Wang J, Zhang B (2023) RefFinder: a web-based tool for comprehensively analyzing and identifying reference genes. Funct Integr Genomics 23:125. https://doi.org/10.1007/s10142-023-01055-7
doi: 10.1007/s10142-023-01055-7 pubmed: 37060478
Yang F, Zhao J, Luo X, Li T, Wang Z, Wei Q, Lu H, Meng Y, Cai K, Lu L, Lu Y, Chen L, Sooranna SR, Luo L, Song J, Meng L (2021) Transcriptome profiling reveals B-lineage cells contribute to the poor prognosis and metastasis of clear cell renal cell carcinoma. Front Oncol 11:731896. https://doi.org/10.3389/fonc.2021.731896
doi: 10.3389/fonc.2021.731896 pubmed: 34485161 pmcid: 8416254
Zhang Z, Wuethrich A, Wang J, Korbie D, Lin LL, Trau M (2021) Dynamic monitoring of EMT in CTCs as an Indicator of cancer metastasis. Anal Chem 93:16787–16795. https://doi.org/10.1021/acs.analchem.1c03167
doi: 10.1021/acs.analchem.1c03167 pubmed: 34889595
Zhao H, Li S, Wang G, Zhao W, Zhang D, Wang F, Li W, Sun L (2019) Study of the mechanism by which dinaciclib induces apoptosis and cell cycle arrest of lymphoma Raji cells through a CDK1-involved pathway. Cancer Med 8:4348–4358. https://doi.org/10.1002/cam4.2324
doi: 10.1002/cam4.2324 pubmed: 31207099 pmcid: 6675732

Auteurs

Quan Gu (Q)

Nanjing Medical University Affiliated Cancer Hospital and Research Center for Clinical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, 42 BaiZiTing Road, Nanjing, Jiangsu, 210000, People's Republic of China.

Jianzhong Wu (J)

Nanjing Medical University Affiliated Cancer Hospital and Research Center for Clinical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, 42 BaiZiTing Road, Nanjing, Jiangsu, 210000, People's Republic of China.

Heng Xu (H)

Jiangsu Provincial Institute of Materia Medica, Nanjing Tech University, Nanjing, Jiangsu, China.

Haixia Cao (H)

Nanjing Medical University Affiliated Cancer Hospital and Research Center for Clinical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, 42 BaiZiTing Road, Nanjing, Jiangsu, 210000, People's Republic of China.

Junying Zhang (J)

Nanjing Medical University Affiliated Cancer Hospital and Research Center for Clinical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, 42 BaiZiTing Road, Nanjing, Jiangsu, 210000, People's Republic of China.

Changwen Jing (C)

Nanjing Medical University Affiliated Cancer Hospital and Research Center for Clinical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, 42 BaiZiTing Road, Nanjing, Jiangsu, 210000, People's Republic of China.

Zhuo Wang (Z)

Nanjing Medical University Affiliated Cancer Hospital and Research Center for Clinical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, 42 BaiZiTing Road, Nanjing, Jiangsu, 210000, People's Republic of China.

Mengjie Du (M)

Jiangsu Provincial Institute of Materia Medica, Nanjing Tech University, Nanjing, Jiangsu, China.

Rong Ma (R)

Nanjing Medical University Affiliated Cancer Hospital and Research Center for Clinical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, 42 BaiZiTing Road, Nanjing, Jiangsu, 210000, People's Republic of China. ailuo06@126.com.

Jifeng Feng (J)

Nanjing Medical University Affiliated Cancer Hospital and Research Center for Clinical Oncology, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, 42 BaiZiTing Road, Nanjing, Jiangsu, 210000, People's Republic of China. jifeng_feng@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH